Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect.
1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
2Department of Surgery, CHA University, Bundang, Korea
Meeting: 2017 American Transplant Congress
Abstract number: A83
Keywords: Hepatocellular carcinoma, IgG, Liver transplantation, Survival
Session Information
Session Name: Poster Session A: Clinical Science: Liver - Hepatocellular Carcinoma and Cholangiocarcinoma Malignancies
Session Type: Poster Session
Date: Saturday, April 29, 2017
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Hall D1
Introduction: Liver transplantation (LT) is increasing treatment option for hepatocellular carcinoma (HCC) in East Asia. Over-immunosuppression is risk factor for oncologic outcome after transplantation and the recurrent HCC is the major cause of graft failure and patient death. But, there are few report comparing the recurrence of HCC after ABO-incompatible (ABOi) LT and ABO-compatible (ABOc) LT. We analyzed post-transplantation recurrence and overall survival of HCC after ABOi and ABOc liver transplantation. Methods:A total 119 recipients with HCC who underwent liver transplantation between January 2010 and December 2015 in Severance hospital were retrospectively reviewed. Among 119 patients, 24 patients underwent ABOi LT. We compared the characteristics and recurrence free survival of HCC after ABOi and ABOc liver LT. The results: There was no significant difference of characteristics between ABOc and ABOi LT. Among 119 patients, 22 patients (18.5%) recurrend after LT. 15.8% of patients underwent ABOc LT and 29.2% of patients underwent ABOi LT were recurred. Among 119 patients, 17 patients (14.3%) were dead or experienced graft failure after LT. 13.7% of patients underwent ABOc LT and 16.7% of patients underwent ABOi LT were dead or experienced graft failure. When we compare recurrence free survival rate and overall survival with patients within Milan criteria and above Milan criteria, there were no difference between ABOc and ABOi LT. Conclusion: The HCC recurrence and overall survival of ABOi LT were comparable to those of ABOc LT. ABO-incompatible liver transplantation is safe and feasible for hepatocellular carcinoma patients.
ABOc(N=95) | ABOi(N=24) | p | |
Sex(M) | 84.2% | 87.5% | 0.934 |
age | 54.7±6.4 | 54.8±5.5 | 0.969 |
Milan criteria(within,%) | 78.9 | 83.3 | 0.846 |
AFP | 64.2±264.1 | 71.3±153.9 | 0.866 |
T1,2:3A,B(%) | 78.9:7.4 | 91.7:4.2 | 0.631 |
Recur(%) | 15.8 | 29.2 | |
Recurrence free survival | 30.4±15.9 | 31.5±16.7 | 0.778 |
Graft fail/death(%) | 13.7 | 16.7 | |
Overall survival | 32.2±15.2 | 34.0±16.0 | 0.617 |
CITATION INFORMATION: Lee J, Lee J, Song S, Kwon S.-K, Kim D, Lee J, Kim M, Choi G, Choi J, Han D, Kim S, Joo D. Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Lee J, Lee J, Song S, Kwon S-K, Kim D, Lee J, Kim M, Choi G, Choi J, Han D, Kim S, Joo D. Is There Any Difference Between ABO-Incompatible and ABO-Compatible Liver Transplantation? Oncologic Aspect. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/is-there-any-difference-between-abo-incompatible-and-abo-compatible-liver-transplantation-oncologic-aspect/. Accessed November 21, 2024.« Back to 2017 American Transplant Congress